Hepatitis c virus infection: 10 years after the discovery of the virus

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 5, 2001, Pages 465-471

  Ramadori, Giuliano ^a   Meier, Volker ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cirrhosis; Hepatitis C virus; Prevalence

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; RIBAVIRIN;

BLOOD DONOR; BLOOD TRANSFUSION; CHRONICITY; DISEASE MARKER; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MASS SCREENING; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SEXUAL BEHAVIOR; VIRUS CLASSIFICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PREVALENCE; RIBAVIRIN; RISK FACTORS;

EID: 0035012543     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200105000-00001     Document Type: Article

References (86)

1. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767-770.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
3. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
4. Alter HJ, Houghton M. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med 2000; 6: 1082-1086.
5. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285: 26-30.
6. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C. et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 2451-2455.
7. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991; 88: 5547-5551.
8. Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 1994; 68: 3631-3641.
9. Shimotohno K, Tanji Y, Hirowatari Y, Komoda Y, Kato N, Hijikata M. Processing of the hepatitis C virus precursor protein. J Hepatol 1995; 22: 87-92.
10. Mizushima H, Hijikata M, Tanji Y, Kimura K, Shimotohno K. Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J Virol 1994; 68: 2731-2734.
11. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N. et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993; 67: 4665-4675.
12. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA 1993; 90: 10583-10587.
13. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993; 67: 4017-4026.
14. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993; 67: 3835-3844.
15. Wang C, Siddiqui A. Structure and function of the hepatitis C virus internal ribosome entry site. Curr Top Microbiol Immunol 1995; 203: 99-115.
16. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B. et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-2399.
17. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C. et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
18. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ. et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884-892.
19. McOmish F, Chan SW, Dow BC, Gillon J, Frame WD, Crawford RJ. et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993; 33: 7-13.
20. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH. et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994; 20: 1405-1411.
21. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25: 735-739.
22. Viazov S, Kuzin S, Paladi N, Tchernovetsky M, Isaeva E, Mazhul L. et al. Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol 1997; 53: 36-40.
23. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122: 161-168.
24. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S. et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-290.
25. Riestra S, Fernandez E, Leiva P, Garcia S, Ocio G, Rodrigo L. Prevalence of hepatitis C virus infection in the general population of northern Spain. Eur J Gastroenterol Hepatol 2001; 13: 477-481.
26. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
27. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F. et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26: 1006-1011.
28. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P. et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-1398.
29. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J. et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 1607-1610.
30. Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tinelli C. et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J Hepatol 1995; 22: 691-695.
31. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci USA 1993; 90: 8234-8238.
32. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G. et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993; 74: 661-668.
33. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
34. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C. et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499.
35. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G. et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
36. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87.
37. Huang L, Koziel MJ. Immunology of hepatitis C virus infection. Curr Opin Gastroenterol 2000; 16: 558-564.
38. Schweyer S, Mihm S, Radzun HJ, Hartmann H, Fayyazi A. Liver infiltrating T lymphocytes express interferon gamma and inducible nitric oxide synthase in chronic hepatitis C virus infection. Gut 2000; 46: 255-259.
39. Baroni GS, Pastorelli A, Manzin A, Benedetti A, Marucci L, Solforosi L. et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999; 19: 212-219.
40. Ksontini R, Colagiovanni DB, Josephs MD, Edwards CK, Tannahill CL, Solorzano CC. et al. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. J Immunol 1998; 160: 4082-4089.
41. Chen YL, Yu CK, Lei HY. Propionibacterium acnes induces acute TNF alpha-mediated apoptosis of hepatocytes followed by inflammatory T-cell-mediated granulomatous hepatitis in mice. J Biomed Sci 1999; 6: 349-356.
42. Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 1997; 27: 30-35.
43. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62-65.
44. Zeuzem S, Teuber G, Lee JH, Ruster B, Roth WK. Risk factors for the transmission of hepatitis C. J Hepatol 1996; 24: 3-10.
45. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L. et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.
46. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F. et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research). Eur J Gastroenterol Hepatol 2000; 12: 667-678.
47. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-914.
48. Alter MJ, Coleman PJ, Alexander WJ, Kramer E, Miller JK, Mandel E. et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262: 1201-1205.
49. Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F. et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982; 145: 886-893.
50. Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY. et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264: 2231-2235.
51. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ. et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905.
52. Thomas DL, Gruninger SE, Siew C, Joy ED, Quinn TC. Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. Am J Med 1996; 100: 41-45.
53. Shapiro CN, Tokars JI, Chamberland ME. Use of the hepatitis-B vaccine and infection with hepatitis B and C among orthopaedic surgeons. The American Academy of Orthopaedic Surgeons Serosurvey Study Committee. J Bone Joint Surg Am 1996; 78: 1791-1800.
54. Buigescu L, Mihaila M, Topala D. Significance of epidemiological ways of transmission of HCV infection. J Hepatol 1997; 26 (suppl 1): 231.
55. Warunek W, Librant-Suska M, Krukowiecki J, Zejc-Bajsarowicz M, Janas-Skulina U, Garlicki A. Epidemiologic and clinical characteristics of patients with hepatitis type C on the bases of selected parameters. Folia Med Cracov 1996; 37: 71-79.
56. Speiciene D, Ambrozaits A, Irnius A, Semuchiniene T, Anuseviciene R. Hepatitis C virus infection in chronic liver diseases of various etiology in Lithuania. Prevalence and risk factors. Acta Med Lithuania 1995; 4: 10-17.
57. Laskus T, Radkowski M, Lupa E, Slusarczyk J, Cianciara J, Halama G. et al. Prevalence of markers of hepatotropic viruses among drug addicts in Warsaw, Poland. J Hepatol 1992; 15: 114-117.
58. Ambrozaits A, Zagminas K, Balciunaite G, Widell A. Hepatitis C in Lithuania: incidence, prevalence, risk factors and viral genotypes. Clin Diagn Virol 1995; 4: 273-284.
59. Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol 1998; 93: 597-600.
60. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology 1999; 116: 893-899.
61. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M. et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317: 437-441.
62. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M. et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356: 904-907.
63. Prieto M, Olaso V, Verdu C, Cordoba J, Gisbert C, Rayon M. et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413-417.
64. Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R. et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27: 853-856.
65. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000; 95: 1545-1550.
66. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995; 15: 64-69.
67. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C. et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136.
68. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J. et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830.
69. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A. et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
70. Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999; 30: 979-983.
71. Levine RA. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998; 129: 323-326.
72. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997; 315: 453-458.
73. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133: 665-675.
74. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J. et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
75. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP. et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506.
76. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
77. Mihm S, Hartmann H, Fayyazi A, Ramadori G. Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio. Dig Dis Sci 1996; 41: 1256-1264.
78. Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R. Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection. J Med Virol 1999; 58: 227-234.
79. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503-524.
80. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM. et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218.
81. Fukuma T, Enomoto N, Marumo F, Sato C. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology 1998; 28: 1147-1153.
82. Mihm S, Monazahian M, Grethe S, Meier V, Thomssen R, Ramadori G. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses. J Med Virol 2000; 61: 29-36.
83. Davis GL. Current therapy for chronic hepatitis C. Gastroenterology 2000; 118: S104-S114.
84. Wietzke-Braun P, Meier V, Braun F, Ramadori G. Combination of '‘low-dose’' ribavirin and interferon alpha-2a therapy followed by interferon alpha-2a monotherapy in chronic hepatitis C virus-infected non-responders and relapsers after interferon alpha-2a monotherapy. Hepatology 2000; 32: 353A.
85. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P. et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137.
86. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999; 131: 696-701.